Tech Company Financing Transactions

EPIRUS Biopharmaceuticals Funding Round

EPIRUS Biopharmaceuticals, based in Boston, secured $36 million in funding from Livzon Mabpharm, 5AM Ventures and Adage Capital Management.

Transaction Overview

Announced On
4/17/2014
Transaction Type
Venture Equity
Amount
$36,000,000
Round
Series B
Proceeds Purpose
Through this transaction, we gain access to additional financial resources as well as clinical trial experience in the rheumatoid arthritis space. Our combined team is committed to expanding patient access to important medications.

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
699 Boylston Street 11th Floor
Boston, MA 02199
USA
Phone
Undisclosed
Email Address
Overview
The biopharmacuticals industry is approaching an unprecedented biologics patent cliff, with emerging markets forging their own regulatory landscapes. EPIRUS is seizing the opportunity with a new business model that adapts to the changing dynamics and regulations of today's market conditions.
Profile
EPIRUS Biopharmaceuticals LinkedIn Company Profile
Social Media
EPIRUS Biopharmaceuticals Company Twitter Account
Company News
EPIRUS Biopharmaceuticals News
Facebook
EPIRUS Biopharmaceuticals on Facebook
YouTube
EPIRUS Biopharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chairman
Geoff Duyk
  Geoff Duyk LinkedIn Profile  Geoff Duyk Twitter Account  Geoff Duyk News  Geoff Duyk on Facebook
Chief Executive Officer
Amit Munshi
  Amit Munshi LinkedIn Profile  Amit Munshi Twitter Account  Amit Munshi News  Amit Munshi on Facebook
VP - Bus. Development
Gale Clark
  Gale Clark LinkedIn Profile  Gale Clark Twitter Account  Gale Clark News  Gale Clark on Facebook
VP - Bus. Development
Nick Plumeridge
  Nick Plumeridge LinkedIn Profile  Nick Plumeridge Twitter Account  Nick Plumeridge News  Nick Plumeridge on Facebook
VP - Manufacturing
Suman Patel
  Suman Patel LinkedIn Profile  Suman Patel Twitter Account  Suman Patel News  Suman Patel on Facebook


 

 

Browse more venture capital transactions:

Prev: 4/17/2014: SKIT venture capital transaction
Next: 4/18/2014: Profectus BioSciences venture capital transaction

 

Share this article

 


About Database of VC Transactions

We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary